Hyaluronidase (Keraform) - ISTA

Drug Profile

Hyaluronidase (Keraform) - ISTA

Alternative Names: Keraform

Latest Information Update: 13 May 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ISTA Pharmaceuticals
  • Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
  • Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Keratoconus

Most Recent Events

  • 22 Feb 2005 Suspended - Preclinical for Keratoconus in USA (Ophthalmic)
  • 24 Jul 2003 No development reported - Preclinical for Keratoconus in USA (Ophthalmic)
  • 29 May 2000 Preclinical development for Keratoconus in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top